Holen Sie sich die Stockscreener-App
27.90
2.96%
-0.85
Viridian Therapeutics Inc Aktie (VRDN) Neueste Nachrichten
Published on: 2026-02-13 20:43:42 - mfd.ru
Viridian Therapeutics, Inc. (VRDN) Stock Analysis: 42% Potential Upside Amidst Breakthrough Biotechnology Advances - DirectorsTalk Interviews
Street Watch: What are the future prospects of Viridian Therapeutics IncJuly 2025 Catalysts & Expert Curated Trade Setup Alerts - baoquankhu1.vn
How Viridian Therapeutics Inc. (VRDN) Affects Rotational Strategy Timing - Stock Traders Daily
Analysts Offer Insights on Healthcare Companies: Veracyte (VCYT), Sarepta Therapeutics (SRPT) and Viridian Therapeutics (VRDN) - The Globe and Mail
Viridian Therapeutics' (VRDN) Buy Rating Reiterated at Needham & Company LLC - MarketBeat
VRDN: Needham Reiterates Buy Rating with Maintained Price Target - GuruFocus
Performance Recap: Can Alerus Financial Corporation stock outperform in a bear marketMarket Trend Report & Verified Technical Signals - baoquankhu1.vn
Analysts Offer Insights on Healthcare Companies: Alphatec Holdings (ATEC), Viridian Therapeutics (VRDN) and Enovis (ENOV) - The Globe and Mail
Viridian Therapeutics (VRDN) Receives Updated Analyst Rating fro - GuruFocus
Wells Fargo & Company Forecasts Strong Price Appreciation for Viridian Therapeutics (NASDAQ:VRDN) Stock - MarketBeat
Viridian Therapeutics (VRDN) Stock Analysis: Exploring a Promising 26% Upside with Strong Buy Ratings - DirectorsTalk Interviews
Y Intercept Hong Kong Ltd Buys 52,414 Shares of Viridian Therapeutics, Inc. $VRDN - MarketBeat
Analysts Have Conflicting Sentiments on These Healthcare Companies: Intellia Therapeutics (NTLA) and Viridian Therapeutics (VRDN) - The Globe and Mail
Profit Review: Is WEX Inc stock a smart retirement pickJuly 2025 Market Mood & Weekly Consistent Profit Watchlists - baoquankhu1.vn
Viridian Therapeutics, Inc. $VRDN Stock Position Reduced by J. Safra Sarasin Holding AG - MarketBeat
Viridian Therapeutics (NASDAQ:VRDN) Sets New 1-Year HighHere's Why - MarketBeat
Evercore ISI raises Viridian Therapeutics stock price target on subQ TED potential - Investing.com Canada
Viridian Therapeutics, Inc. (VRDN) Investor Outlook: Strong Buy Ratings and 26.51% Potential Upside - DirectorsTalk Interviews
Viridian Therapeutics: Cautious Optimism As Key Milestones Approach (Rating Downgrade) - Seeking Alpha
(VRDN) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Pullback Watch: What are Viridian Therapeutics Incs earnings expectationsJuly 2025 Update & Expert-Curated Trade Recommendations - baoquankhu1.vn
Viridian Therapeutics, Inc. (NASDAQ:VRDN) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Evercore Maintains Viridian Therapeutics(VRDN.US) With Buy Rating, Cuts Target Price to $44 - 富途资讯
Viridian Therapeutics, Inc.'s (NASDAQ:VRDN) Business Is Trailing The Industry But Its Shares Aren't - 富途资讯
Did FDA Priority Review and EU Push for Thyroid Eye Drug Just Shift Viridian Therapeutics' (VRDN) Investment Narrative? - Sahm
SG Americas Securities LLC Acquires 49,981 Shares of Viridian Therapeutics, Inc. $VRDN - MarketBeat
Viridian Therapeutics stock hits 52-week high at $34.06 By Investing.com - Investing.com Nigeria
Responsive Playbooks and the VRDN Inflection - Stock Traders Daily
Viridian Therapeutics stock jumps to a 52-week high as VRDN traders zero in on June FDA deadline - TechStock²
Viridian Therapeutics (NASDAQ:VRDN) Reaches New 52-Week HighStill a Buy? - MarketBeat
Viridian Therapeutics stock hits 52-week high at $34.06 - Investing.com
Market Review: Is Viridian Therapeutics Inc stock a good pick for beginnersPortfolio Return Report & Capital Efficiency Focused Ideas - baoquankhu1.vn
Viridian Therapeutics, Inc. (VRDN): Growth Potential in Biotechnology with an 81,958% Revenue Surge - DirectorsTalk Interviews
Will Viridian Therapeutics Inc. stock continue upward momentumJuly 2025 Decliners & Real-Time Buy Zone Alerts - Улправда
Viridian Therapeutics (NASDAQ:VRDN) Upgraded by UBS Group to "Strong-Buy" Rating - MarketBeat
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)January 8, 2026 - BioSpace
Assessing Viridian Therapeutics (VRDN) Valuation After FDA Priority Review For Veligrotug - Sahm
What MACD trends signal for Viridian Therapeutics Inc. (1S1) stockPortfolio Performance Report & Expert Curated Trade Setup Alerts - ulpravda.ru
Will Viridian Therapeutics Inc. stock continue dividend increasesJuly 2025 Short Interest & Low Drawdown Trading Techniques - ulpravda.ru
Is Viridian Therapeutics Inc. stock attractive after correctionCPI Data & Technical Entry and Exit Alerts - Улправда
How Viridian Therapeutics Inc. stock compares to market leaders2025 Trading Volume Trends & Expert Approved Momentum Ideas - Улправда
Viridian Therapeutics, Inc.Common Stock (NQ: VRDN - FinancialContent
Why CHRO stock attracts strong analyst attention - Улправда
Can Viridian Therapeutics Inc. stock deliver strong Q4 earningsQuarterly Market Review & Real-Time Chart Pattern Alerts - Улправда
VRDN: Truist Securities Lowers Price Target but Maintains Buy Ra - GuruFocus
Viridian Therapeutics (NASDAQ:VRDN) Price Target Lowered to $40.00 at Truist Financial - MarketBeat
Why Viridian Therapeutics Inc. stock is in analyst buy zonePortfolio Gains Report & Smart Investment Allocation Insights - Улправда
Oklahoma City NewsThe Oklahoman - FinancialContent
UBS Initiates Coverage of Viridian Therapeutics (VRDN) with Buy Recommendation - Nasdaq
Will Viridian Therapeutics Inc. stock deliver consistent dividendsLong-Term Growth Stocks & Turn Market Volatility into Wealth - Улправда
VRDN: UBS Initiates Coverage with a 'Buy' Rating and $50 Price T - GuruFocus
Why Viridian Therapeutics Inc. stock remains resilientHigh Beta Stocks & Outstanding Portfolio Tips - Улправда
Free cash flow per share of Viridian Therapeutics, Inc. – DUS:1S1 - TradingView — Track All Markets
1.12%
0.87%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):